Literature DB >> 14567600

Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study.

Sergey Spektor1, Samuel Agus, Vladimir Merkin, Shlomo Constantini.   

Abstract

OBJECT: The goal of this paper was to investigate a possible relationship between the consumption of low-dose aspirin (LDA) and traumatic intracranial hemorrhage in an attempt to determine whether older patients receiving prophylactic LDA require special treatment following an incidence of mild-to-moderate head trauma.
METHODS: Two hundred thirty-one patients older than 60 years of age, who arrived at the emergency department with a mild or moderate head injury (Glasgow Coma Scale [GCS] Scores 13-15 and 9-12, respectively), were included in the study. One hundred ten patients were receiving prophylactic LDA (100 mg/day) and these formed the aspirin-treated group. One hundred twenty-one patients were receiving no aspirin, and these formed the control group. There was no statistically significant difference between the two groups with respect to age, sex, mechanism of trauma, or GCS score on arrival at the emergency department. Most of the patients sustained the head injury from falls (88.2% of patients in the aspirin-treated group and 85.1% of patients in the control group), and had external signs of head trauma such as bruising or scalp laceration (80.9% of patients in the aspirin-treated group and 86.8% of patients in the control group). All patients underwent similar neurological examinations and computerized tomography (CT) scanning of the head. The CT scans revealed evidence of traumatic intracranial hemorrhage in 27 (24.5%) patients in the aspirin-treated group and in 31 patients (25.6%) in the control group. Surgical intervention was required for five patients in each group (4.5% of patients in the aspirin-treated group and 4.1% of patients in the control group). A surprising number of the patients who arrived with GCS Score 15 were found to have traumatic intracranial hemorrhage, as revealed by CT scanning (11.5% of patients in the aspirin-treated group and 16.5% of patients in the control group). Surgery, however, was not necessary for any of these patients.
CONCLUSIONS: There was no statistically significant difference in the frequency or types of traumatic intracranial hemorrhage between patients who had received aspirin prophylaxis and those who had not. The authors conclude that LDA does not increase surgically relevant parenchymal or meningeal bleeding following moderate and minor head injury in patients older than 60 years of age.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567600     DOI: 10.3171/jns.2003.99.4.0661

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  Effects of Pre-Injury Anti-Platelet Agents on Short-Term Outcome of Patients with Mild Traumatic Brain Injury: A Cohort Study.

Authors:  Davood Farsi; Parviz Karimi; Mani Mofidi; Babak Mahshidfar; Mahdi Rezai; Peyman Hafezimoghadam; Saeed Abbasi
Journal:  Bull Emerg Trauma       Date:  2017-04

2.  Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.

Authors:  Phillip V Parry; Phillip A Choi; Joshua S Bauer; David M Panczykowski; Ava M Puccio; David O Okonkwo
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

3.  Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages.

Authors:  A Cantalapiedra; O Gutierrez; J I Tortosa; M Yañez; M Dueñas; E Fernandez Fontecha; M J Peñarrubia; L J García-Frade
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

Review 4.  Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review.

Authors:  Daniel K Nishijima; Shahriar Zehtabchi; Jeanette Berrong; Eric Legome
Journal:  J Trauma Acute Care Surg       Date:  2012-06       Impact factor: 3.313

5.  Treatment of acute subdural hematoma.

Authors:  Carter Gerard; Katharina M Busl
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

Review 6.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

7.  Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy.

Authors:  Jeremy L Holzmacher; Cassandra Reynolds; Mayur Patel; Patrick Maluso; Seth Holland; Nathaniel Gamsky; Henry Moore; Elizabeth Acquista; Matthew Carrick; Richard Amdur; Heather Hancock; Michael Metzler; Julie Dunn; Babak Sarani
Journal:  Brain Inj       Date:  2018-01-17       Impact factor: 2.311

8.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2016-04-12       Impact factor: 9.097

9.  Recent changes in risk factors of chronic subdural hematoma.

Authors:  Yang-Won Sim; Kyung-Soo Min; Mou-Seop Lee; Young-Gyu Kim; Dong-Ho Kim
Journal:  J Korean Neurosurg Soc       Date:  2012-09-30

Review 10.  Clinical review: Traumatic brain injury in patients receiving antiplatelet medication.

Authors:  Christopher Beynon; Daniel N Hertle; Andreas W Unterberg; Oliver W Sakowitz
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.